A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas, and Endometrial Cancers.
Phase of Trial: Phase II
Latest Information Update: 15 May 2017
At a glance
- Drugs Letrozole (Primary) ; Ribociclib (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 08 May 2017 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.
- 21 Jan 2017 Planned primary completion date changed from 1 Jul 2021 to 1 Jun 2021.